HOME >> BIOLOGY >> NEWS
Treatments for urinary infections leave bacteria bald, happy and vulnerable

enetic mutation that allows it to survive," Pinkner explains. "We think that pilicides will greatly reduce the pressure to develop resistance and have already shown in the lab that they have no effect on E. coli's growth or metabolic state."

Pinkner notes that all Gram-negative bacteria, including Yersinia pesitis (plague), Salmonella, and Klebsiella pneumoniae (pneumonia and burn and urinary tract infections) make pili and may be susceptible to the same treatments. Keeping the target of the drug specifically aimed at a virulence factor not essential for growth reduces the chances for general resistance to spread, Pinkner asserts. He also notes that such drugs will have fewer effects on bacteria that benefit the host by contributing to healthy human physiology.

"For example, there are bacteria in the intestinal tract that aid in metabolism and the normal function of the intestine, which also helps prevent this niche from being occupied by pathogenic bacteria," he explains. "Given the rise in antibiotic resistance, it is critical to design antimicrobials for the future that target the bad bacteria but leave the good ones alone."


'"/>

Contact: Michael Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
20-Dec-2006


Page: 1 2 3

Related biology news :

1. Treatments have same target, different responses for lung cancer patients with genetic mutation
2. Attack is the best defence against urinary tract infection
3. Injecting stem cells from a womans own muscle may effectively treat urinary incontinence
4. Study demonstrates rapid diagnosis of urinary tract infections with biosensor technology
5. Progress toward a new remedy for chronic urinary tract infections?
6. UCSB researchers advance understanding of urinary tract infections
7. Bugs-eye-view of urinary tract reveals E.coli infection genes
8. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate
9. Injection drug use and HIV and HCV infections among Ontario prison inmates
10. Injection drug use the most important risk factor for HIV and HCV infections among Quebec prisoners
11. Mucins stand guard against gut infections

Post Your Comments:
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/20/2015)... DUBLIN , Mar. 19, 2015 Research and Markets ... the "Iris Biometrics - Global Strategic Business Report" ... worldwide markets for Iris Biometrics in US$ Thousands. The report ... , Japan , Europe ... East , and Latin America . ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
(Date:4/20/2015)... Calif. , April 20, 2015  Ardelyx, ... company focused on cardio-renal, gastrointestinal and metabolic diseases, ... MRCP, has joined the Company,s Board of Directors. ... and board level experience, having built and led ... development, regulatory approval and into healthcare systems globally. ...
(Date:4/20/2015)... 20, 2015  Eli Lilly and Company (NYSE: ... targeted cancer therapies, reflecting Lilly,s diverse oncology pipeline, during ... 2015, held April 18-22 in Philadelphia ... Patients" is the theme of this year,s AACR meeting ... broadening its portfolio of therapies that accelerate the pace ...
(Date:4/20/2015)... 2015 - Development of a ... the VOLVOX Platform - To be Presented on Tuesday, ...  Supramolecular Assembly of Antibody-drug Conjugates Using an anti-HER2 Monoclonal ... Sunday, Apr 19, 1:00 PM EST Invictus ... today announced that the company,s novel computational platform technology ...
(Date:4/20/2015)... 2015 Sinovac Biotech Ltd. (Nasdaq: SVA), a ... its unaudited financial results for the fourth quarter and ... Quarter 2014 Financial Highlights(Compared to the fourth quarter 2013) ... decrease of 11.4% from $22.9 million in the prior ... H5N1 pandemic influenza vaccine of $0.1 million in the ...
Breaking Biology Technology:Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18
Cached News: